D. Douer, The epidemiology of acute promyelocytic leukaemia, Best Practice & Research Clinical Haematology, vol.16, issue.3, pp.357-367, 2003.
DOI : 10.1016/S1521-6926(03)00065-3

J. Otero, S. Santillana, and G. Fereyros, High frequency of acute promyelocytic leukemia among Latinos with acute myeloid leukemia, Blood, vol.88, p.377, 1996.

J. Tomas and J. Fernandez-ranada, About the increased frequency of acute promyelocytic leukemia among Latinos: the experience from a center in Spain, Blood, vol.88, pp.2357-2358, 1996.

G. Ruiz-arguelles, Promyelocytic leukemia in Mexican Mestizos, Blood, vol.89, pp.348-349, 1997.

E. Estey, P. Thall, and H. Kantarjian, Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia, Leukemia, vol.11, issue.10, pp.1661-1664, 1997.
DOI : 10.1038/sj.leu.2400783

P. Hernandez, M. Milanes, E. Svarch, G. Martinez, and J. Ballester, High relative proportion of acute promyelocytic leukemia in children: experience of a multicenter study in Cuba, Leukemia Research, vol.24, issue.8, pp.739-740, 2000.
DOI : 10.1016/S0145-2126(00)00012-6

A. Roosevelt, J. Douglas, and L. Brown, The migrations and adaptations of the first Americans: Clovis and pre-clovis views from South American The First Americans: The Pleistocene Colonization of the New World, pp.159-223

D. Douer, S. Santillana, and L. Ramezani, Acute promyelocytic leukaemia in patients originating in Latin America is associated with an increased frequency of the bcr1 subtype of the PML/RARalpha fusion gene, British Journal of Haematology, vol.84, issue.4, pp.563-570, 2003.
DOI : 10.1016/0092-8674(91)90113-D

G. Ruiz-arguelles, J. Garces-eisele, V. Reyes-nunez, J. Gomez-rangel, and G. Ruiz-delgado, More on Geographic Hematology: The Breakpoint Cluster Regions of the PML/RAR?? Fusion Gene in Mexican Mestizo Patients with Promyelocytic Leukemia are Different from Those in Caucasians, Leukemia & Lymphoma, vol.52, issue.1, pp.1365-1368, 2004.
DOI : 10.1159/000205529

W. Boza, G. Cruz, M. Saenz, and C. Umana, High incidence of acute promyelocytic leukemia in the Caucasian population: The Costa Rica experience, American Journal of Hematology, vol.7, issue.1, pp.96-97, 2004.
DOI : 10.1093/oxfordjournals.annonc.a058400

J. Mejia-arangure, M. Bonilla, and R. Lorenzana, Incidence of leukemias in children from El Salvador and Mexico City between 1996 and 2000: Population-based data, BMC Cancer, vol.37, issue.1, p.33, 2005.
DOI : 10.1002/mpo.1217

M. Sierra, A. Alonso, and M. Odero, Geographic differences in the incidence of cytogenetic abnormalities of acute myelogenous leukemia (AML) in Spain, Leukemia Research, vol.30, issue.8, pp.943-948, 2006.
DOI : 10.1016/j.leukres.2005.12.025

X. Thomas, D. Fiere, and E. Archimbaud, Influence of increased body mass index on drug toxicity in patients with acute promyelocytic leukemia, Leukemia, vol.12, issue.9, pp.1503-1506, 1998.
DOI : 10.1038/sj.leu.2401126

A. Pulsoni, L. Pagano, L. Coco, F. Avvisati, G. Mele et al., Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience, Blood, vol.100, issue.6, pp.1972-1978, 2002.
DOI : 10.1182/blood-2001-12-0312

M. Beaumont, M. Sanz, P. Carli, F. Maloisel, X. Thomas et al., Therapy-Related Acute Promyelocytic Leukemia, Journal of Clinical Oncology, vol.21, issue.11, pp.2123-2160, 2003.
DOI : 10.1200/JCO.2003.09.072

A. Mistry, C. Felix, R. Whitmarsh, A. Mason, A. Reiter et al., DNA Topoisomerase II in Therapy-Related Acute Promyelocytic Leukemia, New England Journal of Medicine, vol.352, issue.15, pp.1529-1567, 2005.
DOI : 10.1056/NEJMoa042715

S. Hasan, A. Mays, T. Ottone, A. Ledda, L. Nasa et al., Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis, Blood, vol.112, issue.8, pp.3383-90, 2008.
DOI : 10.1182/blood-2007-10-115600

A. Mays, N. Osheroff, Y. Xiao, J. Wiemels, C. Felix et al., Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia, Blood, vol.115, issue.2, pp.326-356, 2010.
DOI : 10.1182/blood-2009-07-235051

E. Ammatuna, P. Montesinos, S. Hasan, S. Ramadan, J. Esteve et al., Presenting features and treatment outcome of acute promyelocytic leukemia arising after multiple sclerosis, Haematologica, vol.96, issue.4, pp.621-626, 2011.
DOI : 10.3324/haematol.2010.036657

M. Joannides, A. Mays, A. Mistry, S. Hasan, A. Reiter et al., MOLECULAR PATHOGENESIS OF SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA, Mediterranean Journal of Hematology and Infectious Diseases, vol.3, issue.1, p.2011045, 2011.
DOI : 10.4084/mjhid.2011.045

A. Biondi, A. Luciano, R. Bassan, D. Mininni, G. Specchia et al., CD2 expression in acute promyelocytic leukemia is associated with microgranular morphology (FAB M3v) but not with any PML gene breakpoint, Leukemia, vol.9, pp.1461-1466, 1995.

R. Foley, P. Soamboonsrup, R. Carter, A. Benger, R. Meyer et al., CD34-positive acute promyelocytic leukemia is associated with leukocytosis, microgranular/hypogranular morphology, expression of CD2 and bcr3 isoform, American Journal of Hematology, vol.94, issue.1, pp.34-41, 2001.
DOI : 10.1046/j.1365-2141.1996.d01-1838.x

P. Lin, S. Hao, L. Medeiros, E. Estey, S. Pierce et al., Expression of CD2 in Acute Promyelocytic Leukemia Correlates With Short Form of PML-RAR?? Transcripts and Poorer Prognosis, American Journal of Clinical Pathology, vol.121, issue.3, pp.402-407, 2004.
DOI : 10.1309/XC8P9M8NKQDT38LB

F. Albano, A. Mestice, A. Pannunzio, F. Lanza, B. Martino et al., The biological characteristics of CD34+CD2+ adult acute promyelocytic leukemia and the CD34?CD2? hyergranular and microgranular (M3v) phenotypes, Haematologica, vol.91, pp.311-316, 2006.

P. Montesinos, C. Rayon, E. Vellenga, S. Brunet, T. Gonzalez et al., Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens, Blood, vol.117, issue.6, pp.1799-1805, 2011.
DOI : 10.1182/blood-2010-04-277434

T. Ono, A. Takeshita, Y. Kishimoto, H. Kiyoi, M. Okada et al., Expression of CD56 is an unfavorable prognostic factor for acute promyelocytic leukemia with higher initial white blood cell counts, Cancer Science, vol.120, issue.1, pp.97-104, 2014.
DOI : 10.1182/blood-2012-02-410746

M. Breccia, D. Propris, M. Minotti, C. Stefanizzi, C. Raponi et al., Aberrant phenotypic expression of CD15 and CD56 identifies poor prognostic acute promyelocytic leukemia patients, Leukemia Research, vol.38, issue.2, pp.194-197, 2014.
DOI : 10.1016/j.leukres.2013.11.008

S. De-botton, S. Chevret, M. Sanz, H. Dombret, X. Thomas et al., Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial, British Journal of Haematology, vol.84, issue.3, pp.801-807, 2000.
DOI : 10.1056/NEJM199710093371501

H. De-the, C. Chomienne, M. Lanotte, L. Degos, and A. Dejean, The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor ?? gene to a novel transcribed locus, Nature, vol.347, issue.6293, pp.558-61, 1990.
DOI : 10.1038/347558a0

J. Borrow, A. Goddard, D. Sheer, and E. Solomon, Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17, Science, vol.249, issue.4976, pp.1577-80, 1990.
DOI : 10.1126/science.2218500

H. De-the, C. Lavau, A. Marchio, C. Chomienne, L. Degos et al., The PML-RARalpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell, pp.675-84, 1991.

J. Kane, D. Head, L. Balazs, M. Hulshof, T. Motroni et al., Molecular analysis of the PML/RARalpha chimeric gene in pediatric acute promyelocytic leukemia, Leukemia, vol.10, issue.8, pp.1296-302, 1996.

R. Gallagher, C. Willman, J. Slack, J. Andersen, Y. Li et al., Association of PML-RAR alpha fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study, Blood, vol.90, pp.1656-1663, 1997.

C. Chomienne, P. Ballerini, N. Balitrand, M. Daniel, P. Fenaux et al., All-trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: structure-function relationship, Blood, vol.76, issue.9, pp.1710-1717, 1990.

D. Mangelsdorf, C. Thummel, M. Beato, P. Herrlich, G. Schutz et al., The nuclear receptor superfamily: The second decade, Cell, vol.83, issue.6, pp.835-844, 1995.
DOI : 10.1016/0092-8674(95)90199-X

P. Chambon, A decade of molecular biology of retinoic acid receptors., The FASEB Journal, vol.10, issue.9, 1996.
DOI : 10.1096/fasebj.10.9.8801176

L. Nagy, H. Kao, D. Chakravarti, R. Lin, C. Hassig et al., Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell, pp.373-80, 1997.

B. Farboud, H. Hauksdottir, Y. Wu, and M. Privalsky, Isotype-Restricted Corepressor Recruitment: a Constitutively Closed Helix 12 Conformation in Retinoic Acid Receptors ?? and ?? Interferes with Corepressor Recruitment and Prevents Transcriptional Repression, Molecular and Cellular Biology, vol.23, issue.8, 2003.
DOI : 10.1128/MCB.23.8.2844-2858.2003

S. Onate, S. Tsai, M. Tsai, O. Malley, and B. , Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science, pp.1354-1361, 1995.

T. Yao, G. Ku, N. Zhou, R. Scully, and D. Livingston, The nuclear hormone receptor coactivator SRC-1 is a specific target of p300., Proceedings of the National Academy of Sciences, vol.93, issue.20, pp.10626-10657, 1996.
DOI : 10.1073/pnas.93.20.10626

P. Kastner, H. Lawrence, C. Waltzinger, N. Ghyselinck, P. Chambon et al., Positive and negative regulation of granulopoiesis by endogenous RARalpha, Blood, vol.97, issue.5, pp.1314-1334, 2001.
DOI : 10.1182/blood.V97.5.1314

A. Kakizuka, W. Miller, J. Umesono, K. Warrell, R. et al., Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell, pp.663-74, 1991.

G. Meroni and G. Diez-roux, TRIM/RBCC, a novel class of ???single protein RING finger??? E3 ubiquitin ligases, BioEssays, vol.15, issue.11, pp.1147-57, 2005.
DOI : 10.4049/jimmunol.170.7.3653

A. Reymond, G. Meroni, A. Fantozzi, G. Merla, S. Cairo et al., The tripartite motif family identifies cell compartments, The EMBO Journal, vol.20, issue.9, pp.2140-51, 2001.
DOI : 10.1093/emboj/20.9.2140

S. Hatakeyama, TRIM proteins and cancer, Nature Reviews Cancer, vol.121, issue.11, pp.792-804, 2011.
DOI : 10.1172/JCI45213

P. Kastner, A. Perez, Y. Lutz, C. Rochette-egly, M. Gaub et al., Structure, localization and transcriptional properties of two classes of retinoic acid receptor alpha fusion proteins in acute promyelocytic leukemia (APL): structural similarities with a new family of oncoproteins, Embo J. Feb, vol.11, issue.2, pp.629-671, 1992.

S. Nisole, M. Maroui, X. Mascle, M. Aubry, and M. Chelbi-alix, Differential Roles of PML Isoforms, Frontiers in Oncology, vol.3, p.125, 2013.
DOI : 10.3389/fonc.2013.00125

L. Ivanschitz, Y. Takahashi, F. Jollivet, O. Ayrault, L. Bras et al., PML IV/ARF interaction enhances p53 SUMO-1 conjugation, activation, and senescence, Proceedings of the National Academy of Sciences, vol.3, issue.7, pp.14278-83, 2015.
DOI : 10.1128/MCB.01064-14

URL : http://www.pnas.org/content/112/46/14278.full.pdf

W. Condemine, Y. Takahashi, L. Bras, M. De-the, and H. , A nucleolar targeting signal in PML-I addresses PML to nucleolar caps in stressed or senescent cells, Journal of Cell Science, vol.120, issue.18, pp.3219-3246, 2007.
DOI : 10.1242/jcs.007492

V. Lallemand-breitenbach and H. De-the, PML Nuclear Bodies, Cold Spring Harbor Perspectives in Biology, vol.2, issue.5, p.661, 2010.
DOI : 10.1101/cshperspect.a000661

URL : https://hal.archives-ouvertes.fr/hal-00102123

A. Ishov, A. Sotnikov, D. Negorev, O. Vladimirova, N. Neff et al., Pml Is Critical for Nd10 Formation and Recruits the Pml-Interacting Protein Daxx to This Nuclear Structure When Modified by Sumo-1, The Journal of Cell Biology, vol.8, issue.2, pp.221-255, 1999.
DOI : 10.1038/24628

V. Lallemand-breitenbach, J. Zhu, F. Puvion, M. Koken, N. Honore et al., -Induced Pml or Pml/Retinoic Acid Receptor ?? Degradation, The Journal of Experimental Medicine, vol.73, issue.12, pp.1361-71, 2001.
DOI : 10.1038/sj.onc.1202366

URL : http://jem.rupress.org/content/jem/193/12/1361.full.pdf

V. Fogal, M. Gostissa, P. Sandy, P. Zacchi, T. Sternsdorf et al., Regulation of p53 activity in nuclear bodies by a specific PML isoform, The EMBO Journal, vol.19, issue.22, pp.6185-95, 2000.
DOI : 10.1093/emboj/19.22.6185

A. Guo, P. Salomoni, J. Luo, A. Shih, S. Zhong et al., The function of PML in p53-dependent apoptosis, Nature Cell Biology, vol.18, issue.10, pp.730-736, 2000.
DOI : 10.1093/emboj/18.20.5609

M. Pearson, R. Carbone, C. Sebastiani, M. Cioce, M. Fagioli et al., PML regulates p53 acetylation and premature senescence induced by oncogenic Ras, Nature, vol.391, issue.6792, pp.207-217, 2000.
DOI : 10.1038/35901

E. De-stanchina, E. Querido, M. Narita, R. Davuluri, P. Pandolfi et al., PML Is a Direct p53 Target that Modulates p53 Effector Functions, Molecular Cell, vol.13, issue.4, pp.523-558, 2004.
DOI : 10.1016/S1097-2765(04)00062-0

A. Insinga, S. Monestiroli, S. Ronzoni, R. Carbone, M. Pearson et al., Impairment of p53 acetylation, stability and function by an oncogenic transcription factor, The EMBO Journal, vol.23, issue.5, pp.1144-54, 2004.
DOI : 10.1038/sj.emboj.7600109

S. Hubackova, Z. Novakova, K. Krejcikova, M. Kosar, J. Dobrovolna et al., Regulation of the PML tumor suppressor in drug-induced senescence of human normal and cancer cells by JAK/STAT-mediated signaling, Cell Cycle, vol.9, issue.15, pp.3085-99, 2010.
DOI : 10.4161/cc.9.15.12521

C. Du, R. Redner, M. Cooke, and C. Lavau, Overexpression of wild-type retinoic acid receptor alpha (RARalpha) recapitulates retinoic acid-sensitive transformation of primary myeloid progenitors by acute promyelocytic leukemia RARalpha-fusion genes, Blood. Jul, vol.1594, issue.2, pp.793-802, 1999.

H. De-the and Z. Chen, Acute promyelocytic leukaemia: novel insights into the mechanisms of cure, Nature Reviews Cancer, vol.112, issue.11, pp.775-83, 2010.
DOI : 10.1016/j.bbagrm.2009.07.001

D. Kamashev, D. Vitoux, D. The, and H. , PML???RARA-RXR Oligomers Mediate Retinoid and Rexinoid/cAMP Cross-Talk in Acute Promyelocytic Leukemia Cell Differentiation, The Journal of Experimental Medicine, vol.6, issue.8, 2004.
DOI : 10.1073/pnas.180290497

J. Martens, A. Brinkman, F. Simmer, K. Francoijs, A. Nebbioso et al., PML- RARalpha/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia. Cancer Cell, Feb, vol.1717, issue.2, pp.173-85, 2010.

Z. Chen, N. Brand, A. Chen, S. Chen, J. Tong et al., Fusion between a novel Kruppel-like zinc finger gene and the retinoic acid receptor-alpha locus due to a variant t(11;17) translocation associated with acute promyelocytic leukaemia, Embo J, vol.12, issue.3, pp.1161-1168, 1993.

R. Redner, Variations on a theme: the alternate translocations in APL, Leukemia, vol.16, issue.10, 2002.
DOI : 10.1038/sj.leu.2402720

Y. Yamamoto, S. Tsuzuki, M. Tsuzuki, K. Handa, Y. Inaguma et al., BCOR as a novel fusion partner of retinoic acid receptor alpha in a t(X;17)(p11;q12) variant of acute promyelocytic leukemia, Blood, vol.116, issue.20, pp.4274-83, 2010.
DOI : 10.1182/blood-2010-01-264432

D. Won, S. Shin, C. Park, S. Jang, H. Chi et al., OBFC2A/RARA: a novel fusion gene in variant acute promyelocytic leukemia, Blood, vol.121, issue.8, pp.1432-1437, 2013.
DOI : 10.1182/blood-2012-04-423129

J. Bernard, M. Weil, M. Boiron, C. Jacquillat, G. Flandrin et al., Acute promyelocytic leukemia: results of treatment by daunorubicin, Blood, vol.41, issue.4, pp.489-96, 1973.

P. Flynn, W. Miller, D. Weisdorf, D. Arthur, R. Banning et al., Retinoic acid treatment ofacute promyelocytic leukemia: In vitro and in vivo observations, Blood, vol.62, p.1211, 1983.

B. Nilsson, Probable in vivo induction of differentiation by retinoic acid of promyelocytes in acute promyelocytic leukaemia, British Journal of Haematology, vol.38, issue.3, p.365, 1984.
DOI : 10.1016/S0140-6736(77)91415-5

S. Daenen, E. Vellenga, O. Van-dobbenbugh, and M. Halie, Retinoic acid as antileukemic therapy in a patient with acute promyelocytic leukemia and Aspergillus pneumonia, Blood, vol.67, p.559, 1986.

J. Fontana, J. Roger, and J. Durham, The role of 13 cis-retinoic acid in the remission induction of a patient with acute promyelocytic leukemia, Cancer, vol.53, issue.2, p.209, 1986.
DOI : 10.1073/pnas.68.2.378

M. Huang, Y. Ye, S. Chen, J. Chai, J. Lu et al., Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia, Blood, vol.72, issue.2, pp.567-72, 1988.

P. Fenaux, L. Deley, M. Castaigne, S. Archimbaud, E. Chomienne et al., Effect of all trans-retinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group, Blood, vol.82, issue.11, pp.3241-3250, 1993.

P. Fenaux, S. Chevret, A. Guerci, N. Fegueux, H. Dombret et al., Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia, Leukemia, vol.14, issue.8, pp.1371-1378, 2000.
DOI : 10.1038/sj.leu.2401859

P. Fenaux, C. Chastang, S. Chevret, M. Sanz, H. Dombret et al., A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group, Blood, vol.94, issue.4, pp.1192-200, 1999.

F. Mandelli, D. Diverio, G. Avvisati, T. Barbui, A. Biondi et al., Molecular remission in PML/RARa-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy, Blood, vol.90, p.1014, 1997.

A. Kanamaru, Y. Takemoto, M. Tanimoto, N. Asou, K. Kuriyama et al., All trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia, Blood, 1995.

T. Breitman, S. Collins, and B. Keene, Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid, Blood, vol.57, issue.6, pp.1000-1004, 1981.

S. Castaigne, C. Chomienne, M. Daniel, P. Ballerini, R. Berger et al., All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood, pp.1704-1713, 1990.

P. Fenaux, C. Chastang, C. Chomienne, and L. Degos, Tretinoin with chemotherapy in newly diagnosed acute promyelocytic leukaemia, The Lancet, vol.343, issue.8904, p.1033, 1994.
DOI : 10.1016/S0140-6736(94)90151-1

M. Huang, Y. Ye, S. Chen, J. Chai, J. Lu et al., Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia, Blood, vol.72, issue.2, pp.567-72, 1988.

R. Nasr, M. Guillemin, O. Ferhi, H. Soilihi, L. Peres et al., Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation, Nature Medicine, vol.341, issue.12, 2008.
DOI : 10.1038/nm.1891

URL : https://hal.archives-ouvertes.fr/inserm-00350912

J. Ablain, M. Leiva, L. Peres, J. Fonsart, E. Anthony et al., Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies, The Journal of Experimental Medicine, vol.1333, issue.4, pp.647-53, 2013.
DOI : 10.1016/j.ccr.2005.01.005

J. Ablain, K. Rice, H. Soilihi, A. De-reynies, S. Minucci et al., Activation of a promyelocytic leukemia???tumor protein 53 axis underlies acute promyelocytic leukemia cure, Nature Medicine, vol.70, issue.2, pp.167-74, 2014.
DOI : 10.1158/0008-5472.CAN-10-2014

H. Yoshida, K. Kitamura, K. Tanaka, S. Omura, T. Miyazaki et al., Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway, Cancer Res, 1996.

J. Zhu, M. Gianni, E. Kopf, N. Honore, M. Chelbi-alix et al., Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha ) and oncogenic RARalpha fusion proteins, Proceedings of the National Academy of Sciences, vol.90, issue.1, pp.14807-14819, 1999.
DOI : 10.1016/S0092-8674(00)80317-7

E. Kopf, J. Plassat, V. Vivat, H. De-the, P. Chambon et al., Dimerization with Retinoid X Receptors and Phosphorylation Modulate the Retinoic Acid-induced Degradation of Retinoic Acid Receptors ?? and ?? through the Ubiquitin-Proteasome Pathway, Journal of Biological Chemistry, vol.19, issue.43, pp.33280-33288, 2000.
DOI : 10.1016/S0092-8674(00)80708-4

C. Nervi, F. Ferrara, M. Fanelli, M. Rippo, B. Tomassini et al., Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein, Blood, vol.92, issue.7, pp.2244-51, 1998.

C. Nervi, F. Ferrara, M. Fanelli, M. Rippo, B. Tomassini et al., Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein, Blood, vol.92, issue.7, pp.2244-51, 1998.

J. Zhu, V. Lallemand-breitenbach, and H. De-the, Pathways of retinoic acid- or arsenic trioxide-induced PML/RAR?? catabolism, role of oncogene degradation in disease remission, Oncogene, vol.20, issue.49, pp.7257-65, 2001.
DOI : 10.1073/pnas.94.8.3978

T. Akagi, L. Shih, M. Kato, N. Kawamata, G. Yamamoto et al., Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations, Blood, vol.113, issue.8, pp.1741-1749, 2009.
DOI : 10.1182/blood-2007-12-130260

S. Karnan, S. Tsuzuki, H. Kiyoi, H. Tagawa, R. Ueda et al., Genomewide array-based comparative genomic hybridization analysis of acute promyelocytic leukemia, Genes, Chromosomes and Cancer, vol.97, issue.4, pp.420-425, 2006.
DOI : 10.1002/gcc.20309

C. Niu, H. Yan, T. Yu, H. Sun, J. Liu et al., Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients, Blood, vol.94, issue.10, pp.3315-3339, 1999.

P. Zheng, K. Wang, Q. Zhang, Q. Huang, Y. Du et al., Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia, Proceedings of the National Academy of Sciences, vol.102, issue.1, pp.7653-7658, 2005.
DOI : 10.1182/blood-2002-09-2725

M. Gianni, M. Koken, M. Chelbi-alix, G. Benoit, M. Lanotte et al., Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells, Blood, vol.91, pp.4300-4310, 1998.

D. Santos, G. Kats, L. Pandolfi, and P. , Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia, The Journal of Experimental Medicine, vol.88, issue.13, pp.2793-2802, 2013.
DOI : 10.1073/pnas.96.26.14807

Z. Shen, Z. Shi, J. Fang, B. Gu, J. Li et al., All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia, Proceedings of the National Academy of Sciences, vol.39, issue.2 Suppl 1, pp.5328-5363, 2004.
DOI : 10.1053/shem.2002.33611

J. Hu, Y. Liu, C. Wu, F. Xu, Z. Shen et al., Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia, Proceedings of the National Academy of Sciences, vol.10, issue.12, pp.3342-3349, 2009.
DOI : 10.1200/JCO.2003.04.036

H. Iland, K. Bradstock, S. Supple, A. Catalano, M. Collins et al., All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4), Blood, vol.120, issue.8, pp.1570-1580, 2012.
DOI : 10.1182/blood-2012-02-410746

E. Estey, G. Garcia-manero, A. Ferrajoli, S. Faderl, S. Verstovsek et al., Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia, Blood, vol.107, issue.9, pp.3469-3473, 2006.
DOI : 10.1182/blood-2005-10-4006

F. Ravandi, E. Estey, J. Cortes, O. Brien, S. Pierce et al., Phase II study of alltrans retinoic acid (ATRA), arsenic trioxide (ATO), with or without gemtuzumab ozogamicin (GO) for the frontline therapy of patients with acute promyelocytic leukemia (APL), Blood (ASH Annual Meeting Abstracts), vol.116, 2010.

M. Andersen and J. Pedersen-bjergaard, Therapy-related MDS and AML in acute promyelocytic leukemia, Blood, vol.100, issue.5, pp.1928-1929, 2002.
DOI : 10.1182/blood-2002-03-0962

G. Garcia-manero, H. Kantarjian, S. Kornblau, and E. Estey, Therapy-related myelodysplastic syndrome or acute myelogenous leukemia in patients with acute promyelocytic leukemia (APL), Leukemia, vol.16, issue.9
DOI : 10.1038/sj.leu.2402616

R. Latagliata, M. Petti, S. Fenu, M. Mancini, M. Spiriti et al., Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem, Blood, vol.99, issue.3, pp.822-824, 2002.
DOI : 10.1182/blood.V99.3.822

P. Montesinos, J. Gonzalez, J. Gonzalez, C. Rayon, E. De-lisa et al., -Retinoic Acid and Anthracycline-Based Chemotherapy, Journal of Clinical Oncology, vol.28, issue.24, pp.3872-3879, 2010.
DOI : 10.1200/JCO.2010.29.2268

F. Lo-coco, G. Avvisati, M. Vignetti, C. Thiede, S. Orlando et al., Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia, New England Journal of Medicine, vol.369, issue.2, pp.111-121, 2013.
DOI : 10.1056/NEJMoa1300874

U. Platzbecker, G. Avvisati, L. Cicconi, C. Thiede, F. Paoloni et al., Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non???High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial, Journal of Clinical Oncology, vol.35, issue.6, pp.605-612, 2017.
DOI : 10.1200/JCO.2016.67.1982

A. Vitaliano-prunier, J. Halftermeyer, J. Ablain, A. De-reynies, L. Peres et al., Clearance of PML/RARA-bound promoters suffice to initiate APL differentiation, Blood, vol.124, issue.25, 2014.
DOI : 10.1182/blood-2014-03-561852

F. Quignon, Z. Chen, and H. De-the, Retinoic acid and arsenic: towards oncogene-targeted treatments of acute promyelocytic leukaemia, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol.1333, issue.3, pp.53-61, 1997.
DOI : 10.1016/S0304-419X(97)00025-5

U. Sahin, O. Ferhi, J. M. Benhenda, S. Berthier, C. Jollivet et al., Oxidative stress???induced assembly of PML nuclear bodies controls sumoylation of partner proteins, The Journal of Cell Biology, vol.95, issue.6, pp.931-976, 2014.
DOI : 10.1083/jcb.201305148.dv

URL : https://hal.archives-ouvertes.fr/hal-00992287

V. Lallemand-breitenbach, J. M. Benhenda, S. Nasr, R. Lei, M. Peres et al., Arsenic degrades PML or PML???RAR?? through a SUMO-triggered RNF4/ubiquitin-mediated pathway, Nature Cell Biology, vol.112, issue.5, pp.547-55, 2008.
DOI : 10.1038/nmeth891

M. Tatham, M. Geoffroy, L. Shen, A. Plechanovova, N. Hattersley et al., RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation, Nature Cell Biology, vol.112, issue.5, pp.538-584, 2008.
DOI : 10.1042/BJ20052030

G. Chen, X. Shi, W. Tang, S. Xiong, J. Zhu et al., Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells, Blood, vol.89, issue.9, pp.3345-53, 1997.

G. Chen, J. Zhu, X. Shi, J. Ni, H. Zhong et al., In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins, Blood, vol.88, issue.3, pp.1052-61, 1996.

J. Lehmann-che, C. Bally, and H. De-the, Resistance to Therapy in Acute Promyelocytic Leukemia, New England Journal of Medicine, vol.371, issue.12, pp.1170-1172, 2014.
DOI : 10.1056/NEJMc1409040

E. Goto, A. Tomita, F. Hayakawa, A. Atsumi, H. Kiyoi et al., Missense mutations in PML- RARA are critical for the lack of responsiveness to arsenic trioxide treatment. Blood, pp.1600-1609, 2011.

H. Zhu, Y. Qin, and X. Huang, Resistance to Arsenic Therapy in Acute Promyelocytic Leukemia, New England Journal of Medicine, vol.370, issue.19, pp.1864-1870, 2014.
DOI : 10.1056/NEJMc1316382

L. Adès, A. Guerci, E. Raffoux, M. Sanz, P. Chevallier et al., Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience, Blood, vol.115, issue.9, pp.1690-1696, 2010.
DOI : 10.1182/blood-2009-07-233387

M. Tallman, J. Andersen, C. Schiffer, F. Appelbaum, J. Feusner et al., All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol, Blood, vol.100, issue.13, pp.4298-302, 2002.
DOI : 10.1182/blood-2002-02-0632

G. Avvisati, F. Lo-coco, F. Paoloni, M. Petti, D. Diverio et al., AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance, Blood, vol.117, issue.18, pp.4716-4741, 2011.
DOI : 10.1182/blood-2010-08-302950

M. Sanz, P. Montesinos, E. Vellenga, C. Rayón, J. De-la-serna et al., Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group, Blood, vol.112, issue.8, pp.3130-3134, 2008.
DOI : 10.1182/blood-2008-05-159632

M. Sanz, P. Montesinos, C. Rayón, A. Holowiecka, J. De-la-serna et al., Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome, Blood, vol.115, issue.25, pp.5137-5183, 2010.
DOI : 10.1182/blood-2010-01-266007

E. Rego, H. Kim, G. Ruiz-argüelles, M. Undurraga, U. Mdel et al., Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL. Blood, pp.1935-1978, 2013.

H. Iland, M. Collins, K. Bradstock, S. Supple, A. Catalano et al., Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial, The Lancet Haematology, vol.2, issue.9, pp.357-66, 2015.
DOI : 10.1016/S2352-3026(15)00115-5

J. De-la-serna, P. Montesinos, E. Vellenga, C. Rayón, R. Parody et al., Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin, Blood, vol.111, issue.7, pp.3395-402, 2008.
DOI : 10.1182/blood-2007-07-100669

B. Powell, B. Moser, W. Stock, R. Gallagher, C. Willman et al., Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710, Blood, vol.116, issue.19, pp.3751-3758, 2010.
DOI : 10.1182/blood-2010-02-269621

S. Lehmann, A. Ravn, L. Carlsson, P. Antunovic, S. Deneberg et al., Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry, Leukemia, vol.88, issue.7, pp.1128-1162, 2011.
DOI : 10.1111/j.1600-0609.2006.00803.x

J. Park, B. Qiao, K. Panageas, M. Schymura, J. Jurcic et al., Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid, Blood, vol.118, issue.5, 2011.
DOI : 10.1182/blood-2011-04-346437

J. Mcclellan, H. Kohrt, S. Coutre, J. Gotlib, R. Majeti et al., Treatment advances have not improved the early death rate in acute promyelocytic leukemia, Haematologica, vol.97, issue.1, pp.133-139, 2012.
DOI : 10.3324/haematol.2011.046490

J. Altman, A. Rademaker, E. Cull, B. Weitner, Y. Ofran et al., Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death, Leukemia Research, vol.37, issue.9, pp.1004-1013, 2013.
DOI : 10.1016/j.leukres.2013.05.007

K. Paulson, A. Serebrin, P. Lambert, J. Bergeron, J. Everett et al., Acute promyelocytic leukaemia is characterized by stable incidence and improved survival that is restricted to patients managed in leukaemia referral centres: a pan-Canadian epidemiological study, British Journal of Haematology, vol.88, issue.5, pp.660-666, 2014.
DOI : 10.1002/cncr.24440

R. Jácomo, R. Melo, F. Souto, E. De-mattos, C. De-oliveira et al., Clinical features and outcomes of 134 Brazilians with acute promyelocytic leukemia who received ATRA and anthracyclines, Haematologica, vol.92, issue.10, pp.1431-1433, 2007.
DOI : 10.3324/haematol.10874

A. Rashidi, M. Riley, T. Goldin, F. Sayedian, M. Bayerl et al., Delay in the administration of all-trans retinoic acid and its effects on early mortality in acute promyelocytic leukemia: Final results of a multicentric study in the United States, Leukemia Research, vol.38, issue.9, 2014.
DOI : 10.1016/j.leukres.2014.06.011

F. Mandelli, R. Latagliata, and G. Avvisati, Treatment of elderly patients (???60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols, Leukemia, vol.99, issue.Suppl 1, pp.1085-1090, 2003.
DOI : 10.1182/blood.V99.3.822

M. Sanz, E. Vellenga, and C. Rayon, All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia, Blood, vol.104, issue.12, pp.3490-3493, 2004.
DOI : 10.1182/blood-2004-04-1642

L. Ades, S. Chevret, D. Botton, S. Thomas, X. Dombret et al., Outcome of acute promyelocytic leukemia treated with all trans retinoic acid and chemotherapy in elderly patients: the European group experience, Leukemia, vol.99, issue.2, pp.230-233, 2005.
DOI : 10.1182/blood.V99.9.3136

R. Latagliata, M. Breccia, P. Fazi, M. Vignetti, D. Raimondo et al., GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors, British Journal of Haematology, vol.47, issue.5, pp.564-572, 2011.
DOI : 10.1080/10428190600807178

T. Ono, A. Takeshita, Y. Kishimoto, H. Kiyoi, M. Okada et al., Long-term outcome and prognostic factors of elderly patients with acute promyelocytic leukemia, Cancer Science, vol.19, issue.11, pp.1974-1978, 2012.
DOI : 10.1038/sj.leu.2403807

E. Lengfelder, W. Hofmann, and F. Nolte, Management of elderly patients with acute promyelocytic leukemia: progress and problems, Annals of Hematology, vol.117, issue.9, pp.1181-1188, 2013.
DOI : 10.1159/000097880

P. Disperati, M. Minden, V. Gupta, A. Schimmer, A. Schuh et al., Acute promyelocytic leukemia in patients aged 70 years and over???A single center experience of unselected patients, Leukemia & Lymphoma, vol.92, issue.8, pp.1654-1658, 2007.
DOI : 10.1002/cncr.21006

F. Forghieri, M. Luppi, and M. Morselli, Acute promyelocytic leukemia in very elderly patients: still a clinical challenge, Leukemia & Lymphoma, vol.10, issue.1, pp.119-121, 2009.
DOI : 10.1182/blood-2005-10-4006

M. Tallman, Treatment of elderly adults with acute promyelocytic leukemia: put the pedal to metal, Leukemia & Lymphoma, vol.50, issue.1, pp.12-13, 2009.
DOI : 10.1182/blood.V99.9.3136

P. Finsinger, M. Breccia, C. Minotti, I. Carmosino, C. Girmenia et al., Acute promyelocytic leukemia in patients aged >70??years: the cure beyond the age, Annals of Hematology, vol.369, issue.2, 2015.
DOI : 10.1056/NEJMoa1300874

M. Breccia, R. Latagliata, L. Cannella, C. Minotti, G. Meloni et al., Early hemorrhagic death before starting therapy in acute promyelocytic leukemia: association with high WBC count, late diagnosis and delayed treatment initiation, Haematologica, vol.95, issue.5, pp.853-854, 2010.
DOI : 10.3324/haematol.2009.017962

A. Burnett, D. Grimwade, E. Solomon, K. Wheatley, and A. Goldstone, Presenting white blood cell counts and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: results of the randomized MRC trial, Blood, vol.93, pp.4131-4143, 1999.

A. Burnett, R. Hills, D. Grimwade, J. Jovanovic, J. Craig et al., Inclusion of chemotherapy in addition to anthracycline in the treatment of acute promyelocytic leukaemia does not improve outcomes: results of the MRC AML15 trial, Leukemia, vol.94, issue.4, pp.843-851, 2013.
DOI : 10.1038/sj.leu.2404501

E. Lengfelder, C. Haferlach, S. Saussele, T. Haferlach, B. Schultheis et al., High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG, Leukemia, vol.95, issue.12, pp.2248-2258, 2009.
DOI : 10.1182/blood-2008-07-168617

E. Lengfelder, B. Hanfstein, C. Haferlach, J. Braess, U. Krug et al., Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group, Annals of Hematology, vol.51, issue.17, pp.41-52, 2013.
DOI : 10.1002/gcc.21961

S. Frankel, A. Eardley, G. Lauwers, M. Weiss, and R. Warrell, The "Retinoic Acid Syndrome" in Acute Promyelocytic Leukemia, Annals of Internal Medicine, vol.117, issue.4, p.292, 1992.
DOI : 10.7326/0003-4819-117-4-292

P. Montesinos, J. Bergua, and E. Vellenga, Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors, Blood, vol.113, issue.4, p.775, 2009.
DOI : 10.1182/blood-2008-07-168617

L. Vahdat, P. Maslak, W. Miller, . Jr, A. Eardley et al., Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid, Blood, vol.84, pp.3843-3849, 1994.

M. Tallman, J. Andersen, C. Schiffer, F. Appelbaum, J. Feusner et al., Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome, Blood, vol.95, pp.90-95, 2000.

L. Camacho, S. Soignet, C. S. Ho, R. Heller, G. Scheinberg et al., Leukocytosis and the Retinoic Acid Syndrome in Patients With Acute Promyelocytic Leukemia Treated With Arsenic Trioxide, Journal of Clinical Oncology, vol.18, issue.13, p.2620, 2000.
DOI : 10.1200/JCO.2000.18.13.2620

J. Cortes, H. Kantarjian, O. Brien, S. Robertson, L. Koller et al., Alltrans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia. Cancer, pp.2946-52, 1994.

G. Avvisati, L. Coco, F. Diverio, D. Falda, M. Ferrara et al., AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study, Blood, vol.88, issue.4, pp.1390-1398, 1996.

S. Frankel, A. Eardley, G. Heller, E. Berman, W. Miller et al., All-trans Retinoic Acid for Acute Promyelocytic Leukemia: Results of the New York Study, Annals of Internal Medicine, vol.120, issue.4, pp.278-86, 1994.
DOI : 10.7326/0003-4819-120-4-199402150-00004

M. Nicolls, L. Terada, R. Tuder, S. Prindiville, and M. Schwarz, Diffuse Alveolar Hemorrhage with Underlying Pulmonary Capillaritis in the Retinoic Acid Syndrome, American Journal of Respiratory and Critical Care Medicine, vol.262, issue.4, pp.1302-1307, 1998.
DOI : 10.1002/jcb.240590802

M. Luesink, J. Pennings, W. Wissink, P. Linssen, P. Muus et al., Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome, Blood, vol.114, issue.27, pp.5512-5533, 2009.
DOI : 10.1182/blood-2009-02-204834

S. De-botton, H. Dombret, M. Sanz, J. Miguel, D. Caillot et al., Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group, Blood, vol.92, issue.8, pp.2712-2720, 1998.

S. De-botton, S. Chevret, V. Coiteux, H. Dombret, M. Sanz et al., Early onset of chemotherapy can reduce the incidence of ATRA syndrome in newly diagnosed acute promyelocytic leukemia (APL) with low white blood cell counts: results from APL 93 trial, Leukemia, vol.6, issue.2, pp.339-381, 2003.
DOI : 10.2307/2344317

J. Wiley and F. Firkin, Reduction of pulmonary toxicity by prednisolone prophylaxis during all-trans retinoic acid treatment of acute promyelocytic leukemia. Australian Leukaemia Study Group, Leukemia, vol.9, pp.774-778, 1995.

R. Jeddi, H. Ghédira, S. Mnif, E. Gouider, P. Fenaux et al., High body mass index is an independent predictor of differentiation syndrome in patients with acute promyelocytic leukemia, Leukemia Research, vol.34, issue.4, pp.545-552, 2010.
DOI : 10.1016/j.leukres.2009.09.017

URL : https://hal.archives-ouvertes.fr/pasteur-01375286

P. Daly, C. Schiffer, and P. Wiernik, Acute promyelocytic leukemia???clinical management of 15 patients, American Journal of Hematology, vol.52, issue.4, pp.347-359, 1980.
DOI : 10.1016/S0025-7125(16)31285-8

L. Hillestad, Acute Promyelocytc Leukemia, Acta Medica Scandinavica, vol.58, issue.3, pp.189-194, 1957.
DOI : 10.1001/jama.1955.02950310038009

H. Kantarjian, M. Keating, R. Walters, E. Estey, K. Mccredie et al., Acute promyelocytic leukemia, The American Journal of Medicine, vol.80, issue.5, pp.789-97, 1986.
DOI : 10.1016/0002-9343(86)90617-0

C. Cordonnier, J. Vernant, B. Brun, M. Heilmann, M. Kuentz et al., Acute promyelocytic leukemia in 57 previously untreated patients. Cancer, pp.18-25, 1985.
DOI : 10.1002/1097-0142(19850101)55:1<18::aid-cncr2820550104>3.0.co;2-b

URL : http://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19850101)55:1<18::AID-CNCR2820550104>3.0.CO;2-B/pdf

M. Petti, G. Avvisati, S. Amadori, M. Baccarani, A. Guarini et al., Acute promyelocytic leukemia: clinical aspects and results of treatment in 62 patients, Haematologica, vol.72, issue.2, pp.151-156, 1987.

R. Stone, M. Maguire, M. Goldberg, J. Antin, D. Rosenthal et al., Complete remission in acute promyelocytic leukemia despite persistence of abnormal bone marrow promyelocytes during induction therapy: experience in 34 patients, Blood, vol.71, issue.3, pp.690-696, 1988.

E. Stein, B. Mcmahon, H. Kwaan, J. Altman, O. Frankfurt et al., The coagulopathy of acute promyelocytic leukaemia revisited, Best Practice & Research Clinical Haematology, vol.22, issue.1, pp.153-163, 2009.
DOI : 10.1016/j.beha.2008.12.007

K. Breen, D. Grimwade, and B. Hunt, The pathogenesis and management of the coagulopathy of acute promyelocytic leukaemia, British Journal of Haematology, vol.72, issue.1, pp.24-36, 2012.
DOI : 10.1111/j.1600-0609.2004.00237.x

H. Dombret, M. Scrobohaci, P. Ghorra, J. Zini, M. Daniel et al., Coagulation disorders associated with acute promyelocytic leukemia: corrective effect of all-trans retinoic acid treatment, Leukemia, vol.7, issue.1, pp.2-9, 1993.

R. Watanabe, M. Murata, N. Takayama, M. Tokuhira, M. Kizaki et al., Long-term follow-up of hemostatic molecular markers during remission induction therapy with all-trans retinoic acid for acute promyelocytic leukemia. Keio Hematology-Oncology Cooperative Study Group (KHOCS) Thromb Haemost, pp.641-646, 1997.

M. Tallman, P. Lefèbvre, R. Baine, M. Shoji, I. Cohen et al., Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia, Journal of Thrombosis and Haemostasis, vol.95, issue.8, 2004.
DOI : 10.7326/0003-4819-117-4-292

A. Falanga, M. Alessio, M. Donati, and T. Barbui, A new procoagulant in acute leukemia, Blood, vol.71, pp.870-875, 1988.

A. Falanga, L. Iacoviello, V. Evangelista, D. Belotti, R. Consonni et al., Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans-retinoic acid, Blood, vol.86, issue.3, pp.1072-81, 1995.

R. Edwards and W. Brande, Procoagulant activity of the VX2 carcinoma: tissue factor activity is expressed by tumor cells, Clin Res, vol.37, p.466, 1989.

K. Andoh, H. Sadakata, T. Uchiyama, N. Narahara, H. Tanaka et al., One-Stage Method for Assay of Tissue Factor Activity of Leukemic Cell with Special Reference to Disseminated Intravascular Coagulation, American Journal of Clinical Pathology, vol.93, issue.5, pp.679-84, 1990.
DOI : 10.1093/ajcp/93.5.679

A. Falanga and F. Rickles, Pathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia, Best Practice & Research Clinical Haematology, vol.16, issue.3, pp.463-82, 2003.
DOI : 10.1016/S1521-6926(03)00059-8

P. Nawroth, D. Handlet, C. Esmon, and D. Stern, Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity., Proceedings of the National Academy of Sciences, vol.83, issue.10, pp.3460-3464, 1986.
DOI : 10.1073/pnas.83.10.3460

M. Bevilacqua, J. Pober, G. Majeau, W. Fiers, R. Cotran et al., Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1., Proceedings of the National Academy of Sciences, vol.83, issue.12, pp.4533-4540, 1986.
DOI : 10.1073/pnas.83.12.4533

A. Schorer, M. Kaplan, G. Rao, and C. Moldow, Interleukin 1 stimulates endothelial cell tissue factor production and expression by a prostaglandin-independent mechanism, Thromb Haemost, vol.56, pp.256-265, 1986.

R. Schleef, M. Bevilacqua, M. Sawdey, M. Gimbrone, . Jr et al., Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1

T. Ikezoe, Pathogenesis of disseminated intravascular coagulation in patients with acute promyelocytic leukemia, and its treatment using recombinant human soluble thrombomodulin, International Journal of Hematology, vol.8, issue.126, pp.27-37
DOI : 10.7326/0003-4819-120-4-199402150-00004

A. Mantovani, F. Bussolino, and E. Dejana, Cytokine regulation of endothelial cell function., The FASEB Journal, vol.6, issue.8, pp.2591-2599, 1992.
DOI : 10.1096/fasebj.6.8.1592209

M. Luesink, J. Pennings, W. Wissink, P. Linssen, P. Muus et al., Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: triggering the differentiation syndrome, Blood, vol.114, issue.27, pp.5512-5521, 2009.
DOI : 10.1182/blood-2009-02-204834

H. Saito, I. Maruyama, S. Shimazaki, Y. Yamamoto, N. Aikawa et al., Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial, Journal of Thrombosis and Haemostasis, vol.61, issue.1, pp.31-41, 2007.
DOI : 10.1046/j.1523-1755.2002.00160.x

M. Shindo, K. Ikuta, L. Addo, S. Ito, M. Fujiya et al., Successful Control of Disseminated Intravascular Coagulation by Recombinant Thrombomodulin during Arsenic Trioxide Treatment in Relapsed Patient with Acute Promyelocytic Leukemia, Case Reports in Hematology, vol.19, issue.18, p.908196, 2012.
DOI : 10.1160/TH10-12-0802

N. Kawano, T. Kuriyama, S. Yoshida, K. Yamashita, H. Ochiai et al., Clinical Features and Treatment Outcomes of Six Patients with Disseminated Intravascular Coagulation Resulting from Acute Promyelocytic Leukemia and Treated with Recombinant Human Soluble Thrombomodulin at a Single Institution, Internal Medicine, vol.52, issue.1, pp.55-62, 2013.
DOI : 10.2169/internalmedicine.52.7978

T. Ikezoe, A. Takeuchi, A. Taniguchi, K. Togitani, and A. Yokoyama, Recombinant human soluble thrombomodulin counteracts capillary leakage associated with engraftment syndrome, Bone Marrow Transplantation, vol.101, issue.4, pp.616-624, 2011.
DOI : 10.1172/JCI200522782

T. Ikezoe, K. Togitani, N. Komatsu, M. Isaka, and A. Yokoyama, Successful treatment of sinusoidal obstructive syndrome after hematopoietic stem cell transplantation with recombinant human soluble thrombomodulin, Bone Marrow Transplantation, vol.82, issue.4, pp.783-788, 2010.
DOI : 10.1172/JCI200522782

J. Zhu, Tissue factors on acute promyelocytic leukemia and endothelial cells are differently regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents, Leukemia, vol.13, issue.7, pp.1062-70, 1999.
DOI : 10.1038/sj.leu.2401448

E. Greeno, R. Bach, and C. Moldow, Apoptosis is associated with increased cell surface tissue factor procoagulant activity, Lab Invest, vol.75, pp.281-289, 1996.

L. Casciola-rosen, A. Rosen, M. Petri, and M. Schlissel, Surface blebs on apoptotic cells are sites of enhanced procoagulant activity: implications for coagulation events and antigenic spread in systemic lupus erythematosus., Proceedings of the National Academy of Sciences, vol.93, issue.4, pp.1624-1629, 1996.
DOI : 10.1073/pnas.93.4.1624

P. Flynn, C. Byrne, T. Baglin, P. Weissberg, and M. Bennett, Thrombin generation by apoptotic vascular smooth muscle cells, Blood, vol.89, pp.4378-4384, 1997.

H. Kwaan, S. Parmar, and J. Wang, Pathogenesis of increased risk of thrombosis in cancer, Semin Thromb Hemost, vol.29, pp.283-290, 2003.

J. Zhou, J. Shi, J. Hou, F. Cao, Y. Zhang et al., Phosphatidylserine exposure and procoagulant activity in acute promyelocytic leukemia, Journal of Thrombosis and Haemostasis, vol.24, issue.4, pp.773-82, 2010.
DOI : 10.1002/cyto.a.20345

A. Kini, L. Peterson, M. Tallman, and M. Lingen, Angiogenesis in acute promyelocytic leukemia: induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid, Blood, vol.97, issue.12, pp.3919-3924, 2001.
DOI : 10.1182/blood.V97.12.3919

K. Alimoghaddam, A. Shariftabrizi, S. Tavangar, Z. Sanaat, S. Rostami et al., Anti-leukemic and anti-angiogenesis efficacy of arsenic trioxide in new cases of acute promyelocytic leukemia, Leukemia & Lymphoma, vol.10, issue.1, pp.81-89, 2006.
DOI : 10.1038/sj.neo.7900123

M. Conese, P. Montemurro, R. Fumarulo, D. Giordano, S. Riccardi et al., Inhibitory effect of retinoids on the generation of procoagulant activity by blood mononuclear phagocytes, Thromb Haemost, vol.66, issue.6, pp.662-667, 1991.

M. Van-aalderen, M. Trappenburg, M. Van-schilfgaarde, P. Molenaar, T. Cate et al., Procoagulant myeloblast-derived microparticles in AML patients: changes in numbers and thrombin generation potential during chemotherapy, Journal of Thrombosis and Haemostasis, vol.5, issue.1, 2011.
DOI : 10.1111/j.1538-7836.2007.02369.x

H. Kwaan and E. Rego, Role of Microparticles in the Hemostatic Dysfunction in Acute Promyelocytic Leukemia, Seminars in Thrombosis and Hemostasis, vol.36, issue.08, pp.36-917, 2010.
DOI : 10.1055/s-0030-1267045

B. Bennett, N. Booth, A. Croll, and A. Dawson, The bleeding disorder in acute promyelocytic leukaemia: fibrinolysis due to u-PA rather than defibrination, British Journal of Haematology, vol.61, issue.4, pp.511-517, 1989.
DOI : 10.1021/bi00628a023

Y. Sakata, T. Murakami, A. Noro, K. Mori, and M. Matsuda, The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia, Blood, vol.77, pp.1949-1957, 1991.

H. Dombret, M. Scrobohaci, M. Daniel, J. Micléa, S. Castaigne et al., In vivo thrombin and plasmin activities in patients with acute promyelocytic leukemia (APL): effect of all-trans retinoic acid (ATRA) therapy, Leukemia, vol.9, pp.19-24, 1995.

J. Menell, G. Cesarman, A. Jacovina, M. Mclaughlin, E. Lev et al., Annexin II and Bleeding in Acute Promyelocytic Leukemia, New England Journal of Medicine, vol.340, issue.13, pp.994-1004, 1999.
DOI : 10.1056/NEJM199904013401303

C. Brownstein, A. Deora, A. Jacovina, R. Weintraub, M. Gertier et al., Annexin II mediates plasminogen-dependent matrix invasion by human monocytes: enhanced expression by macrophages, Blood, vol.103, issue.1, pp.317-324, 2004.
DOI : 10.1182/blood-2003-04-1304

URL : http://www.bloodjournal.org/content/bloodjournal/103/1/317.full.pdf

H. Kwaan, J. Wang, and I. Weiss, Expression of receptors for plasminogen activators on endothelial cell surface depends on their origin, Journal of Thrombosis and Haemostasis, vol.126, issue.2, pp.306-312, 2004.
DOI : 10.1161/01.CIR.84.6.2568

R. Jácomo, B. Santana-lemos, A. Lima, P. Assis, A. Lange et al., Methionine-induced hyperhomocysteinemia reverts fibrinolytic pathway activation in a murine model of acute promyelocytic leukemia, Blood, vol.120, issue.1, pp.207-213, 2012.
DOI : 10.1182/blood-2011-04-347187

W. Schmidt, R. Egbring, and K. Havemann, Effect of elastase-like and chymotrypsin-like neutral proteases from human granulocytes on isolated clotting factors, Thrombosis Research, vol.6, issue.4, pp.315-329, 1975.
DOI : 10.1016/0049-3848(75)90081-X

A. Federici, A. Falanga, A. Lattuada, D. Rocco, N. Barbui et al., Proteolysis of von Willebrand factor is decreased in acute promyelocytic leukaemia by treatment with all-trans-retinoic acid, British Journal of Haematology, vol.92, issue.3, pp.733-739, 1996.
DOI : 10.1046/j.1365-2141.1996.401939.x

A. Federici and D. , The Role of Von Willebrand Factor in the Hemostatic Defect of Acute Promyelocytic Leukemia, Leukemia & Lymphoma, vol.65, issue.5-6, pp.491-499, 1998.
DOI : 10.1073/pnas.89.17.7880

X. Zhang, H. Zhou, J. Wang, L. Yang, Y. Hu et al., Arsenic trioxide, retinoic acid and Ara-c regulated the expression of annexin II on the surface of APL cells, a novel co-receptor for plasminogen/tissue plasminogen activator, Thrombosis Research, vol.106, issue.1, pp.63-70, 2002.
DOI : 10.1016/S0049-3848(02)00075-0

S. Olwill, H. Mcglynn, W. Gilmore, and H. Alexander, All-trans retinoic acid-induced downregulation of annexin II expression in myeloid leukaemia cell lines is not confined to acute promyelocytic leukaemia, British Journal of Haematology, vol.41, issue.2, pp.258-264, 2005.
DOI : 10.1016/S0049-3848(02)00075-0

F. Lo-coco, G. Avvisati, M. Vignetti, M. Breccia, E. Gallo et al., Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group, Blood, vol.116, issue.17, pp.1163171-1163180, 2010.
DOI : 10.1182/blood-2010-03-276196

M. Tallman, Updates on the treatment of acute promyelocytic leukemia, Clin Adv Hematol Oncol, vol.8, issue.2, pp.89-90, 2010.

F. Rodeghiero, G. Avvisati, G. Castaman, T. Barbui, and F. Mandelli, Early deaths and antihemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients, Blood, issue.11, pp.75-2112, 1990.

A. Falanga, M. Marchetti, T. Barbui, and C. W. Smith, Pathogenesis of Thrombosis in Essential Thrombocythemia and Polycythemia Vera: The Role of Neutrophils, Seminars in Hematology, vol.42, issue.4, pp.239-286, 2005.
DOI : 10.1053/j.seminhematol.2005.05.023

T. Barbui, G. Finazzi, and A. Falanga, The management of bleeding and thrombosis in acute leukemia and chronic myeloproliferative disorders, Leukemia, pp.263-82, 2001.

A. Falanga and M. Donati, Pathogenesis of Thrombosis in Patients with Malignancy, International Journal of Hematology, vol.5, issue.suppl 3, pp.137-181, 2001.
DOI : 10.1111/j.1365-2141.1992.tb02978.x

M. Sanz, G. Martín, M. González, A. León, C. Rayón et al., Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group, Blood, vol.103, issue.4, pp.1237-1280, 2004.
DOI : 10.1182/blood-2003-07-2462

S. Hashimoto, T. Koike, W. Tatewaki, Y. Seki, N. Sato et al., Fatal thromboembolism in acute promyelocytic leukemia during all-trans retinoic acid therapy combined with antifibrinolytic therapy for prophylaxis of hemorrhage, Leukemia, 1994.

T. Barbui, G. Finazzi, and A. Falanga, The impact of all-transretinoic acid on the coagulopathy of acute promyelocytic leukemia, Blood, vol.91, pp.3093-102, 1998.

E. Estey, P. Thall, S. Pierce, H. Kantarjian, and M. Keating, Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine., Journal of Clinical Oncology, vol.15, issue.2, pp.483-90, 1997.
DOI : 10.1200/JCO.1997.15.2.483

M. Tallman, J. Andersen, C. Schiffer, F. Appelbaum, J. Feusner et al., -Retinoic Acid in Acute Promyelocytic Leukemia, New England Journal of Medicine, vol.337, issue.15, pp.1021-1029, 1997.
DOI : 10.1056/NEJM199710093371501

M. Sanz, G. Martín, C. Rayón, J. Esteve, M. González et al., A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group, Blood, vol.94, issue.9, pp.3015-3036, 1999.

E. Lengfelder, A. Reichert, and C. Schoch, Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia, Leukemia, vol.14, issue.8, pp.1362-70, 2000.
DOI : 10.1038/sj.leu.2401843

N. Asou, K. Adachi, U. Tamura, A. Kanamaru, S. Kageyama et al., Analysis of prognostic factors in newly diagnosed patients with acute promyelocytic leukemia: the APL92 study of the Japan Adult Leukemia Study Group (JALSG), Cancer Chemotherapy and Pharmacology, vol.48, issue.0, pp.65-71, 2001.
DOI : 10.1007/s002800100308

R. Schlenk, U. Germing, F. Hartmann, A. Glasmacher, J. Fischer et al., High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia, Leukemia, vol.15, issue.6, pp.978-83, 2005.
DOI : 10.1038/sj.leu.2402205

M. Yanada, T. Matsushita, N. Asou, Y. Kishimoto, M. Tsuzuki et al., Severe hemorrhagic complications during remission induction therapy for acute promyelocytic leukemia: incidence, risk factors, and influence on outcome, European Journal of Haematology, vol.77, issue.3, pp.213-222, 2007.
DOI : 10.1111/j.1538-7836.2004.00787.x

G. Avvisati, F. Mandelli, M. Petti, M. Vegna, A. Spadea et al., Idarubicin (4-demethoxydaunorubicin) as single agent for remission induction of previously untreated acute promyelocytic leukemia: A pilot study of the Italian cooperative group GIMEMA, European Journal of Haematology, vol.70, issue.suppl 178, pp.257-60, 1990.
DOI : 10.1056/NEJM198107163050305

B. Rotoli, The GIMEMA protocol LAP (0389) for the treatment of acute promyelocytic leukemia (APL) Preliminary results, Proceedings of the 24th Congress of the International Society of Hematology (Abstract), p.842, 1992.

G. Juliusson, P. Antunovic, A. Derolf, S. Lehmann, L. Mollgard et al., Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry, Blood, vol.113, issue.18, pp.4179-4187, 2009.
DOI : 10.1182/blood-2008-07-172007

M. Sanz and P. Montesinos, Open issues on bleeding and thrombosis in acute promyelocytic leukemia, Thrombosis Research, vol.125, issue.2, pp.51-54, 2010.
DOI : 10.1016/S0049-3848(10)70013-X

C. Percy, . Sk, S. Whelan, D. Parkin, A. Jack et al., International Classification of Diseases for Oncology (ICD-O), World Health, 2000.

B. Falini, L. Flenghi, M. Fagioli, L. Coco, F. Cordone et al., Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the monoclonal antibody PG-M3 (anti- PML). Blood, pp.4046-53, 1997.

F. Santos, A. Dore, A. Lima, A. Garcia, M. Zago et al., Caracter??sticas hematol??gicas e perfil de express??o de ant??genos miel??ides de pacientes com leucemia promieloc??tica aguda: an??lise de fatores progn??sticos para o desenvolvimento da s??ndrome do ??cido retin??ico, Revista da Associa????o M??dica Brasileira, vol.50, issue.3, pp.286-92, 1992.
DOI : 10.1590/S0104-42302004000300036

L. Adès, M. Sanz, S. Chevret, P. Montesinos, P. Chevallier et al., Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results, Blood, vol.111, issue.3, pp.1078-84, 2008.
DOI : 10.1182/blood-2007-07-099978

R. Ribeiro and E. Rego, Management of APL in Developing Countries: Epidemiology, Challenges and Opportunities for International Collaboration, Hematology, vol.2006, issue.1, pp.162-168, 2006.
DOI : 10.1182/asheducation-2006.1.162

R. Rahmé, X. Thomas, C. Recher, N. Vey, J. Delaunay et al., Early death in acute promyelocytic leukemia (APL) in French centers: a multicenter study in 399 patients, Leukemia, vol.166, issue.12, pp.2422-2426, 2014.
DOI : 10.1111/bjh.12931